FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378473295> ?p ?o ?g. }

• W4378473295 endingPage "e006595" @default.
• W4378473295 startingPage "e006595" @default.
• W4378473295 abstract "Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. However, only a portion of patients respond to such treatments. Therefore, it remains a prevailing clinical need to identify factors associated with acquired resistance or lack of response to ICIs. We hypothesized that the immunosuppressive CD71 + erythroid cells (CECs) within the tumor and/or distant ‘out-of-field’ may impair antitumor response. Methods We studied 38 patients with cancer through a phase II clinical trial investigating the effects of oral valproate combined with avelumab (anti-programmed death-ligand 1 (PD-L1)) in virus-associated solid tumors (VASTs). We quantified the frequency/functionality of CECs in blood and biopsies of patients. Also, we established an animal model of melanoma (B16-F10) to investigate the possible effects of erythropoietin (EPO) treatment on anti-PD-L1 therapy. Results We found a substantial expansion of CECs in the blood of patients with VAST compared with healthy controls. We noted that the frequency of CECs in circulation was significantly higher at the baseline and throughout the study in non-responders versus responders to PD-L1 therapy. Moreover, we observed that CECs in a dose-dependent manner suppress effector functions of autologous T cells in vitro. The subpopulation of CD45 + CECs appears to have a more robust immunosuppressive property compared with their CD45 − counterparts. This was illustrated by a stronger expression of reactive oxygen species, PD-L1/PD-L2, and V-domain Ig suppressor of T-cell activation in this subpopulation. Lastly, we found a higher frequency of CECs in the blood circulation at the later cancer stage and their abundance was associated with anemia, and a poor response to immunotherapy. Finally, we report the expansion of CECs in the spleen and tumor microenvironment of mice with melanoma. We found that although CECs in tumor-bearing mice secret artemin, this was not the case for VAST-derived CECs in humans. Notably, our results imply that EPO, a frequently used drug for anemia treatment in patients with cancer, may promote the generation of CECs and subsequently abrogates the therapeutic effects of ICIs (eg, anti-PD-L1). Conclusions Our results demonstrate that anemia by the expansion of CECs may enhance cancer progression. Notably, measuring the frequency of CECs may serve as a valuable biomarker to predict immunotherapy outcomes." @default.
• W4378473295 created "2023-05-27" @default.
• W4378473295 creator A5019634062 @default.
• W4378473295 creator A5026928149 @default.
• W4378473295 creator A5036163767 @default.
• W4378473295 creator A5040822160 @default.
• W4378473295 creator A5053949973 @default.
• W4378473295 creator A5070194877 @default.
• W4378473295 creator A5083751459 @default.
• W4378473295 date "2023-05-01" @default.
• W4378473295 modified "2023-10-01" @default.
• W4378473295 title "CD71⁺erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors" @default.
• W4378473295 cites W1493822493 @default.
• W4378473295 cites W1501784999 @default.
• W4378473295 cites W1757645784 @default.
• W4378473295 cites W1968519475 @default.
• W4378473295 cites W1974872064 @default.
• W4378473295 cites W1981775117 @default.
• W4378473295 cites W1985213644 @default.
• W4378473295 cites W1985908235 @default.
• W4378473295 cites W1991471550 @default.
• W4378473295 cites W1992907775 @default.
• W4378473295 cites W1996722181 @default.
• W4378473295 cites W2002189627 @default.
• W4378473295 cites W2044748328 @default.
• W4378473295 cites W2064126141 @default.
• W4378473295 cites W2066552669 @default.
• W4378473295 cites W2071606440 @default.
• W4378473295 cites W2076606989 @default.
• W4378473295 cites W2083891313 @default.
• W4378473295 cites W2124422993 @default.
• W4378473295 cites W2143841612 @default.
• W4378473295 cites W2168631000 @default.
• W4378473295 cites W2177185177 @default.
• W4378473295 cites W2469758901 @default.
• W4378473295 cites W2482783327 @default.
• W4378473295 cites W2509309434 @default.
• W4378473295 cites W2554479252 @default.
• W4378473295 cites W2567441703 @default.
• W4378473295 cites W2592144107 @default.
• W4378473295 cites W2597872842 @default.
• W4378473295 cites W2609126440 @default.
• W4378473295 cites W2738780043 @default.
• W4378473295 cites W2743794466 @default.
• W4378473295 cites W2744835610 @default.
• W4378473295 cites W2760003250 @default.
• W4378473295 cites W2779931836 @default.
• W4378473295 cites W2782007611 @default.
• W4378473295 cites W2795300421 @default.
• W4378473295 cites W2799755811 @default.
• W4378473295 cites W2805960205 @default.
• W4378473295 cites W2886141713 @default.
• W4378473295 cites W2889138052 @default.
• W4378473295 cites W2893870376 @default.
• W4378473295 cites W2894952817 @default.
• W4378473295 cites W2900834229 @default.
• W4378473295 cites W2903877638 @default.
• W4378473295 cites W2914193935 @default.
• W4378473295 cites W2954157188 @default.
• W4378473295 cites W2990852929 @default.
• W4378473295 cites W3012705781 @default.
• W4378473295 cites W3022745897 @default.
• W4378473295 cites W3025545149 @default.
• W4378473295 cites W3036267792 @default.
• W4378473295 cites W3047346934 @default.
• W4378473295 cites W3107187630 @default.
• W4378473295 cites W3110114858 @default.
• W4378473295 cites W3112961014 @default.
• W4378473295 cites W3129637596 @default.
• W4378473295 cites W3158940958 @default.
• W4378473295 cites W3162177645 @default.
• W4378473295 cites W3174092685 @default.
• W4378473295 cites W3179762195 @default.
• W4378473295 cites W3186407069 @default.
• W4378473295 cites W4220652205 @default.
• W4378473295 cites W4280516985 @default.
• W4378473295 cites W4283690255 @default.
• W4378473295 cites W4292401473 @default.
• W4378473295 cites W71612995 @default.
• W4378473295 doi "https://doi.org/10.1136/jitc-2022-006595" @default.
• W4378473295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37236637" @default.
• W4378473295 hasPublicationYear "2023" @default.
• W4378473295 type Work @default.
• W4378473295 citedByCount "1" @default.
• W4378473295 countsByYear W43784732952023 @default.
• W4378473295 crossrefType "journal-article" @default.
• W4378473295 hasAuthorship W4378473295A5019634062 @default.
• W4378473295 hasAuthorship W4378473295A5026928149 @default.
• W4378473295 hasAuthorship W4378473295A5036163767 @default.
• W4378473295 hasAuthorship W4378473295A5040822160 @default.
• W4378473295 hasAuthorship W4378473295A5053949973 @default.
• W4378473295 hasAuthorship W4378473295A5070194877 @default.
• W4378473295 hasAuthorship W4378473295A5083751459 @default.
• W4378473295 hasBestOaLocation W43784732951 @default.
• W4378473295 hasConcept C121608353 @default.
• W4378473295 hasConcept C126322002 @default.
• W4378473295 hasConcept C143998085 @default.
• W4378473295 hasConcept C203014093 @default.

• next